Format

Send to

Choose Destination
Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):52-61. doi: 10.4269/ajtmh.16-0182. Epub 2016 Oct 17.

Costs and Cost-Effectiveness of Plasmodium vivax Control.

Author information

1
MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom.
2
Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom.
3
Universität Basel, Basel, Switzerland.
4
Swiss Tropical and Public Health Institute, Basel, Switzerland.
5
Global Malaria Programme, World Health Organization, Geneva, Switzerland.

Abstract

The continued success of efforts to reduce the global malaria burden will require sustained funding for interventions specifically targeting Plasmodium vivax The optimal use of limited financial resources necessitates cost and cost-effectiveness analyses of strategies for diagnosing and treating P. vivax and vector control tools. Herein, we review the existing published evidence on the costs and cost-effectiveness of interventions for controlling P. vivax, identifying nine studies focused on diagnosis and treatment and seven studies focused on vector control. Although many of the results from the much more extensive P. falciparum literature can be applied to P. vivax, it is not always possible to extrapolate results from P. falciparum-specific cost-effectiveness analyses. Notably, there is a need for additional studies to evaluate the potential cost-effectiveness of radical cure with primaquine for the prevention of P. vivax relapses with glucose-6-phosphate dehydrogenase testing.

PMID:
28025283
PMCID:
PMC5201223
DOI:
10.4269/ajtmh.16-0182
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Ingenta plc Icon for PubMed Central
Loading ...
Support Center